JP7502337B2 - Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 - Google Patents

Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 Download PDF

Info

Publication number
JP7502337B2
JP7502337B2 JP2021568865A JP2021568865A JP7502337B2 JP 7502337 B2 JP7502337 B2 JP 7502337B2 JP 2021568865 A JP2021568865 A JP 2021568865A JP 2021568865 A JP2021568865 A JP 2021568865A JP 7502337 B2 JP7502337 B2 JP 7502337B2
Authority
JP
Japan
Prior art keywords
mmol
compound
pharma
acceptable salt
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533398A5 (enExample
JP2022533398A (ja
Inventor
ヒルフ，ジャスティン，エー．
ローズ，トリスティン，イー．
バートバーガー，マイケル，ディー．
オーボイル，ブレンダン，エム．
リーブス，コリー，エム．
ローソン，オリバー，シー．
ストルツ，ブライアン，エム．
マクダーモット，マルティナ，エス．
オーブライアン，ニール，エー．
スレイモン，デニス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022533398A publication Critical patent/JP2022533398A/ja
Publication of JP2022533398A5 publication Critical patent/JP2022533398A5/ja
Application granted granted Critical
Publication of JP7502337B2 publication Critical patent/JP7502337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021568865A 2019-05-20 2020-05-20 Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 Active JP7502337B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962850289P 2019-05-20 2019-05-20
US62/850,289 2019-05-20
PCT/US2020/033816 WO2020236940A1 (en) 2019-05-20 2020-05-20 Kras g12c inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2022533398A JP2022533398A (ja) 2022-07-22
JP2022533398A5 JP2022533398A5 (enExample) 2023-05-29
JP7502337B2 true JP7502337B2 (ja) 2024-06-18

Family

ID=73458223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568865A Active JP7502337B2 (ja) 2019-05-20 2020-05-20 Ｋｒａｓ ｇ１２ｃインヒビター及びその使用

Country Status (12)

Country Link
US (1) US20220227738A1 (enExample)
EP (1) EP3972978A4 (enExample)
JP (1) JP7502337B2 (enExample)
KR (1) KR20220038289A (enExample)
CN (1) CN114096544B (enExample)
AU (1) AU2020279253A1 (enExample)
BR (1) BR112021023359A2 (enExample)
CA (1) CA3141604A1 (enExample)
IL (1) IL288200A (enExample)
MX (1) MX2021014177A (enExample)
SG (1) SG11202112790SA (enExample)
WO (1) WO2020236940A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
CN114630832A (zh) * 2019-11-15 2022-06-14 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2021139748A1 (en) * 2020-01-08 2021-07-15 Ascentage Pharma (Suzhou) Co., Ltd. Spirocyclic tetrahydroquinazolines
JP7808058B2 (ja) 2020-06-02 2026-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
WO2022040469A1 (en) * 2020-08-19 2022-02-24 The Trustees Of The Stevens Institute Of Technology Spiro compounds as kras inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
JP2023544450A (ja) 2020-09-23 2023-10-23 エラスカ・インコーポレイテッド 三環式ピリドン及びピリミドン
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN114685502A (zh) 2020-12-25 2022-07-01 由理生物医药（上海）有限公司 作为kras-g12c抑制剂的螺环类化合物
CN114805311B (zh) * 2021-01-21 2024-10-29 苏州亚盛药业有限公司 螺环茚
WO2022240971A2 (en) * 2021-05-11 2022-11-17 1200 Pharma Llc Kras g12d inhibitors and uses thereof
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
CA3237274A1 (en) * 2021-11-09 2023-05-19 1200 Pharma Llc Select kras g12c inhibitors and uses thereof
WO2023099624A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099608A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CA3243798A1 (en) * 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
TW202430179A (zh) 2022-11-21 2024-08-01 美商樹線生物科學公司 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
KR20260041941A (ko) 2023-03-15 2026-03-27 콴타 테라퓨틱스, 인크. Kras 조절 인자 및 이의 용도
WO2025038936A1 (en) 2023-08-17 2025-02-20 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025237091A1 (zh) * 2024-05-17 2025-11-20 中山优理生物医药有限公司 螺环类化合物的制备方法及其中间体
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016532656A (ja) 2013-10-10 2016-10-20 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの阻害剤
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2018143315A1 (ja) 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2018218070A2 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20100298289A1 (en) * 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2898765T3 (es) * 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
EA201992780A1 (ru) * 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
TW201942116A (zh) * 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
US11096939B2 (en) * 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012204A (es) * 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
AU2019320945C1 (en) * 2018-08-16 2021-09-30 F. Hoffmann-La Roche Ag Fused ring compounds
WO2021139748A1 (en) * 2020-01-08 2021-07-15 Ascentage Pharma (Suzhou) Co., Ltd. Spirocyclic tetrahydroquinazolines
WO2022040469A1 (en) * 2020-08-19 2022-02-24 The Trustees Of The Stevens Institute Of Technology Spiro compounds as kras inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016532656A (ja) 2013-10-10 2016-10-20 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの阻害剤
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2018143315A1 (ja) 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2018218070A2 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras

Also Published As

Publication number Publication date
US20220227738A1 (en) 2022-07-21
SG11202112790SA (en) 2021-12-30
IL288200A (en) 2022-01-01
EP3972978A1 (en) 2022-03-30
BR112021023359A2 (pt) 2022-02-01
AU2020279253A1 (en) 2021-12-16
CN114096544A (zh) 2022-02-25
CA3141604A1 (en) 2020-11-26
EP3972978A4 (en) 2023-04-26
CN114096544B (zh) 2025-08-12
JP2022533398A (ja) 2022-07-22
MX2021014177A (es) 2022-04-25
KR20220038289A (ko) 2022-03-28
WO2020236940A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
JP7502337B2 (ja) Ｋｒａｓ ｇ１２ｃインヒビター及びその使用
WO2022115439A1 (en) Kras g12c inhibitors and uses thereof
JP6109969B2 (ja) 新規なピリミジン及びピリジン化合物並びにその利用
JP6609631B2 (ja) 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途
CN115836072A (zh) Kras g12c蛋白的抑制剂和其用途
WO2022242767A1 (zh) 螺环类化合物及其用途
US20220363681A1 (en) Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
CN113286794A (zh) Kras突变蛋白抑制剂
CN118772176A (zh) 一种嘧啶并芳环化合物及其制备方法和用途
AU2014214031B2 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2025078984A1 (en) Substituted tricyclic compounds as kras degraders
KR20100116206A (ko) Ｈｓｐ90 저해제로서의 옥심 유도체
CN106565706B (zh) 一种磺酰胺衍生物及其在药学中的应用
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
WO2022240971A2 (en) Kras g12d inhibitors and uses thereof
CN104557871A (zh) 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CN116964061A (zh) 作为细胞周期蛋白依赖性激酶7（cdk7）抑制剂的三环嘧啶
WO2024023727A1 (en) Novel acc inhibitors
CN116655602A (zh) PI3Kα变构抑制剂
WO2021227904A1 (zh) 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
CN102190669A (zh) 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
CN120530118A (zh) 一种氮杂环烷烃化合物、药物组合物及其用途
WO2023046030A1 (zh) 一种egfr小分子抑制剂、含其的药物组合物及其用途
WO2022216946A1 (en) Mcl1 inhibitors and uses thereof
KR20250170567A (ko) 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240606

R150 Certificate of patent or registration of utility model

Ref document number: 7502337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150